Real-world comparison of standard versus reduced dose apixaban in stroke prevention and bleeding risk in atrial fibrillation patients with chronic kidney disease: A retrospective analysis of TriNetX data.

Author Information

Sameh Gomaa, Tower HealthFollow
Joseph Hellman, Tower HealthFollow
Olutoyin Lawal, Tower HealthFollow
Edward Hovick, Tower HealthFollow
Slawomir Kusmirek, Tower HealthFollow

Keywords:

chronic kidney disease, atrial fibrillation, apixaban, anticoagulation, bleeding, stroke

Recommended Citation

Gomaa, Sameh; Hellman, Joseph; Lawal, Olutoyin; Hovick, Edward; and Kusmirek, Slawomir, "Real-world comparison of standard versus reduced dose apixaban in stroke prevention and bleeding risk in atrial fibrillation patients with chronic kidney disease: A retrospective analysis of TriNetX data." (2024). Tower Health Research Day. 59.
https://scholarcommons.towerhealth.org/th_researchday/2023-2024/online_posters/59

Institutional Review Board/Institutional Animal Care and Use Committee Approved or Exempt

Not Applicable